Batuca, J., Lamy, M., Neves, M., Batista, F., Paiva-Lopes, M. J., Valverde, A. H., … Alves, J. D. (2017). Anti-apolipoprotein A-I (ApoA-I) antibodies have different target epitopes in different clinical conditions. In Atherosclerosis (Vol. 263, pp. e216–e217). Elsevier BV. https://doi.org/10.1016/j.atherosclerosis.2017.06.705

Batuca, Joana, Márcia Lamy, Marisa Neves, Frederico Batista, Ma João Paiva-Lopes, Ana H. Valverde, Margarida Silva, et al. “Anti-apolipoprotein A-I (ApoA-I) antibodies have different target epitopes in different clinical conditions.” In Atherosclerosis, 263:e216–17. Elsevier BV, 2017. https://doi.org/10.1016/j.atherosclerosis.2017.06.705.

Batuca J, Lamy M, Neves M, Batista F, Paiva-Lopes MJ, Valverde AH, et al. Anti-apolipoprotein A-I (ApoA-I) antibodies have different target epitopes in different clinical conditions. In: Atherosclerosis. Elsevier BV; 2017. p. e216–7.

Batuca, Joana, et al. “Anti-apolipoprotein A-I (ApoA-I) antibodies have different target epitopes in different clinical conditions.” Atherosclerosis, vol. 263, Elsevier BV, 2017, pp. e216–17. Crossref, doi:10.1016/j.atherosclerosis.2017.06.705.

Batuca J, Lamy M, Neves M, Batista F, Paiva-Lopes MJ, Valverde AH, Silva M, Mcvey CE, Archer M, Gonçalves J, Barbas A, Bandeiras TM, Carrondo MA, Alves JD. Anti-apolipoprotein A-I (ApoA-I) antibodies have different target epitopes in different clinical conditions. Atherosclerosis. Elsevier BV; 2017. p. e216–e217.